Understand the source comparison
Epithalon vs Pinealon: Full Comparison
The table below breaks down the critical differences across mechanism, research context, and practical considerations. Primary Mechanism Telomerase activation (TERT upregulation) CNS-specific gene regulation (BDNF, NGF, synapsin-1) Entirely separate pathways.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below breaks down the critical differences across mechanism, research context, and practical considerations.
- Primary Mechanism
- Telomerase activation (TERT upregulation)
- CNS-specific gene regulation (BDNF, NGF, synapsin-1)
- Entirely separate pathways. Not redundant
- Target System
- Systemic (all dividing cells)
- Central nervous system (neurons, glia)
- Epithalon is multi-tissue; Pinealon is CNS-selective
- Research Endpoint
- Lifespan extension, cellular senescence delay
- Neuroprotection, cognitive function, post-injury recovery
- Longevity models vs neuroscience models
- Documented Lifespan Effect
- 10–18% median lifespan increase (rodents, invertebrates)
- No measurable effect on lifespan
- Epithalon is the longevity peptide
- Neuroprotective Evidence
- Minimal (indirect via systemic aging delay)
- Strong (22% infarct reduction, BDNF restoration)
- Pinealon outperforms in CNS injury models
- Typical Research Dose (Rodent)
- 5–10 µg/g body weight, every 48 hours
- 50–100 µg/kg, daily for 5–10 days post-injury
- Dosing frequency and timing differ significantly
- Reconstitution pH Sensitivity
- Low (stable pH 5.5–7.0)
- Moderate (optimal pH 6.5–7.0; <6.0 reduces potency)
- Pinealon requires pH adjustment in most protocols
- Storage Stability (Reconstituted)
- 28 days at 2–8°C
- 28 days at 2–8°C (pH-dependent)
- Identical cold-chain requirements
- Clinical Use History
- 30+ years (Russia, observational data)
- 15+ years (Russia, limited RCTs)
- Epithalon has longer clinical track record